Ipodate sodium

Jump to navigation Jump to search
Ipodate sodium
Clinical data
Routes of
oral, Intravenous
ATC code
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Molar mass619.93906 g/mol
3D model (JSmol)
Melting point168-169 °C (-104.2 °F)

WikiDoc Resources for Ipodate sodium


Most recent articles on Ipodate sodium

Most cited articles on Ipodate sodium

Review articles on Ipodate sodium

Articles on Ipodate sodium in N Eng J Med, Lancet, BMJ


Powerpoint slides on Ipodate sodium

Images of Ipodate sodium

Photos of Ipodate sodium

Podcasts & MP3s on Ipodate sodium

Videos on Ipodate sodium

Evidence Based Medicine

Cochrane Collaboration on Ipodate sodium

Bandolier on Ipodate sodium

TRIP on Ipodate sodium

Clinical Trials

Ongoing Trials on Ipodate sodium at Clinical Trials.gov

Trial results on Ipodate sodium

Clinical Trials on Ipodate sodium at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Ipodate sodium

NICE Guidance on Ipodate sodium


FDA on Ipodate sodium

CDC on Ipodate sodium


Books on Ipodate sodium


Ipodate sodium in the news

Be alerted to news on Ipodate sodium

News trends on Ipodate sodium


Blogs on Ipodate sodium


Definitions of Ipodate sodium

Patient Resources / Community

Patient resources on Ipodate sodium

Discussion groups on Ipodate sodium

Patient Handouts on Ipodate sodium

Directions to Hospitals Treating Ipodate sodium

Risk calculators and risk factors for Ipodate sodium

Healthcare Provider Resources

Symptoms of Ipodate sodium

Causes & Risk Factors for Ipodate sodium

Diagnostic studies for Ipodate sodium

Treatment of Ipodate sodium

Continuing Medical Education (CME)

CME Programs on Ipodate sodium


Ipodate sodium en Espanol

Ipodate sodium en Francais


Ipodate sodium in the Marketplace

Patents on Ipodate sodium

Experimental / Informatics

List of terms related to Ipodate sodium

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Ipodate sodium (sodium iopodate) is an iodine-containing radiopaque contrast media used for X-rays. The drug is given orally and the resulting contrast allows for easy resolution of the bile duct and gall bladder. The drug goes by the trade name Oragrafin or Gastrografin.[1]

Other uses

Although not FDA approved, ipodate sodium has been used to treat Graves' disease and thyroid storm, an extreme form of hyperthyroidism.

Graves' disease

Long-term treatment of Graves' disease with ipodate sodium (500 mg, daily) given by mouth reduced levels of T3 and T4 in the patients.[2] This was done with minimal side effects, indicating possible clinical usefulness. Iodine uptake was also noted to return to normal within seven days, indicating control with ipodate with rapid follow up treatment with 131I is feasible.

Thyroid Storm

In emergency situations, ipodate can be administered for thyroid storm. As the ipodate is metabolized, it releases iodine into circulation, helping bring the T3 and T4 levels back down. Ipodate also inhibits the conversion of T4 to T3 (which is more potent). It is not considered a first-line approach, as potassium iodide and beta blockers have less potential for side-effects. Ipodate sodium lacks FDA approval for this use.


  1. http://www.drugs.com/cons/cholecystographic-agent.html
  2. DC Shen, SY Wu, IJ Chopra, HW Huang, LR Shian, TY Bian, CY Jeng and DH Solomon (1985). "Long term treatment of Graves' hyperthyroidism with sodium ipodate". Journal of Clinical Endocrinology & Metabolism. 61 (4): 723–727. doi:10.1210/jcem-61-4-723. PMID 3928675.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>

Template:Contrast media Template:Thyroid therapy